FDA Picks Eli Lilly, Regeneron for Fast-Track Manufacturing Review
The FDA has selected seven companies, including Eli Lilly and Regeneron, for a new pilot program designed to accelerate manufacturing facility reviews.
The U.S. Food and Drug Administration has chosen Eli Lilly and Regeneron as two of the first seven companies tapped for its PreCheck Pilot Program, a new initiative aimed at speeding up the agency's review of new pharmaceutical manufacturing facilities, CNBC reported.
The selection marks a significant step in federal efforts to streamline drug production oversight at a time when manufacturing bottlenecks and supply chain vulnerabilities have drawn heightened scrutiny from regulators and lawmakers alike. By fast-tracking facility reviews, the FDA's pilot program could help bring new medicines to market more quickly while maintaining safety standards.
Read more Defense Lobbyists Fight House Move to Block Contractor Buybacks →
Eli Lilly, a dominant force in the diabetes and weight-loss drug market, and Regeneron, known for breakthrough treatments in oncology and immunology, represent major players whose manufacturing expansions carry broad implications for drug availability nationwide. Their inclusion in the inaugural cohort signals the FDA's intent to work with high-profile, high-volume manufacturers first.
The PreCheck Pilot Program reflects a broader regulatory push to modernize FDA inspection and approval processes, particularly as domestic pharmaceutical manufacturing has become a priority amid ongoing concerns about reliance on foreign drug supply chains. If the pilot proves successful, it could be expanded to include a wider range of manufacturers across the industry.
Continue reading at US Top News and Analysis.
